The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.
Besse L et al. Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S et al. Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.219. [Epub ahead of print].

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.
Díaz T et al. Haematologica. 2017 Jul 27. pii: haematol.2017.164632. doi: 10.3324/haematol.2017.164632. [Epub ahead of print].

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F et al. Cell Oncol (Dordr). 2017 Jul 18. doi: 10.1007/s13402-017-0338-4. [Epub ahead of print].

The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.
Gaoxiang W et al. Cancer Biol Ther. 2017 Jul 18:0. doi: 10.1080/15384047.2017.1345386. [Epub ahead of print].

Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities.
Kampan NC et al. Curr Med Chem. 2017 Jul 12. doi: 10.2174/0929867324666170712160621. [Epub ahead of print].

2,5-Dihydroxyacetophenone Induces Apoptosis of Multiple Myeloma Cells by Regulating the MAPK Activation Pathway.
Ko JH et al. Molecules. 2017 Jul 11;22(7). pii: E1157. doi: 10.3390/molecules22071157.

Involvement of the TGFβ1/Smad2/MMP3 signaling pathway in SB431542-induced inhibition of cell invasion in multiple myeloma RPMI 8226 cells.
Xi H et al. Oncol Lett. 2017 Jul;14(1):541-546. doi: 10.3892/ol.2017.6263. Epub 2017 May 26.

ILF2 Is Upregulated by 1q21 Amplification in Multiple Myeloma.
[No authors listed]. Cancer Discov. 2017 Jul 7. doi: 10.1158/2159-8290.CD-RW2017-128. [Epub ahead of print].

Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.
Du S et al. Oncol Rep. 2017 Aug;38(2):809-818. doi: 10.3892/or.2017.5770. Epub 2017 Jun 30.

Telomere length is positively associated with the expression of IL‑6 and MIP‑1α in bone marrow mesenchymal stem cells of multiple myeloma.
Li S et al. Mol Med Rep. 2017 Jun 29. doi: 10.3892/mmr.2017.6885. [Epub ahead of print].

The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y et al. J Hematol Oncol. 2017 Jul 3;10(1):132. doi: 10.1186/s13045-017-0499-7.

The role of Capon in multiple myeloma.
Shen Y et al. Tumour Biol. 2017 Jul;39(7):1010428317713674. doi: 10.1177/1010428317713674.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM et al. Br J Haematol. 2017 Jul 2. doi: 10.1111/bjh.14807. [Epub ahead of print].

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.
Marchesini M et al. Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29.

In Vitro Apoptosis Induction by Fenofibrate in Lymphoma and Multiple Myeloma.
Schmeel LC et al. Anticancer Res. 2017 Jul;37(7):3513-3520.

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.
Mitra AK et al. Blood Cancer J. 2017 Jun 30;7(6):e581. doi: 10.1038/bcj.2017.56.

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Hao S et al. Mod Pathol. 2017 Jun 30. doi: 10.1038/modpathol.2017.63. [Epub ahead of print].

Down-regulation of long noncoding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma.
Liu H et al. Clin Exp Pharmacol Physiol. 2017 Jun 30. doi: 10.1111/1440-1681.12804. [Epub ahead of print].

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT et al. Oncotarget. 2017 Jul 4;8(27):43602-43616. doi: 10.18632/oncotarget.17115.

Autoantibodies against β1-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients.
Gao W et al. Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1344904. [Epub ahead of print].

Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
Van Veggel M et al. Clin Pharmacokinet. 2017 Jun 30. doi: 10.1007/s40262-017-0565-x. [Epub ahead of print].

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.
Lopes-Aguiar L et al. Blood Cancer J. 2017 Jun 30;7(6):e580. doi: 10.1038/bcj.2017.58.

1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells.
Cafforio P et al. Exp Cell Res. 2017 Jun 29. pii: S0014-4827(17)30353-1. doi: 10.1016/j.yexcr.2017.06.023. [Epub ahead of print].

Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D et al. Curr Opin Hematol. 2017 Jul;24(4):336-344. doi: 10.1097/MOH.0000000000000358.

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A et al. Leukemia. 2017 Jul 5. doi: 10.1038/leu.2017.212. [Epub ahead of print].

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.
Muz B et al. Transl Oncol. 2017 Jun 29;10(4):632-640. doi: 10.1016/j.tranon.2017.04.010. [Epub ahead of print].

Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.
Smol T et al. Mol Cytogenet. 2017 Jul 1;10:26. doi: 10.1186/s13039-017-0327-3. eCollection 2017.